Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma - Related Studies - ClinicalTrials.gov

Skip to Main Content

ClinicalTrials.gov

Home Search Study Topics Glossary


	Full Text View


	Tabular View


	No Study Results Posted


	Related Studies

Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma

This study is ongoing, but not recruiting participants.

Study NCT00410462 Information provided by National Cancer Institute (NCI)

First Received: December 11, 2006 Last Updated: October 8, 2008 History of Changes

Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:

Conditions listed in this trial

Ovarian Cancer
Sarcoma
Small Intestine Cancer

Additional conditions recognized in this trial

Duodenal Neoplasms
Ileal Neoplasms
Intestinal Neoplasms
Jejunal Neoplasms
Ovarian Neoplasms

Interventions listed in this trial

brostallicin
doxorubicin hydrochloride

Additional drug interventions recognized in this trial

Doxorubicin

More general drug interventions related to this trial

Antibiotics, Antineoplastic
Antineoplastic Agents
Pharmacologic Actions
Therapeutic Uses

Sponsors listed in this trial

European Organization for Research and Treatment of Cancer

Back to top of Main Content